aTyr Pharma Inc. (ATYR) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
aTyr Pharma Inc. (ATYR) surged +4.56% to $5.37, trading at 3% of its 52-week range ($4.08 – $44.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Peer-reviewed publication reinforces efzofitimod’s differentiated profile and potential to advance pulmonary sarcoidosis care.SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “
A look at the biggest US stock movers on October 27, 2026, including the top percentage gainers and decliners with prices and context.
Today's gap stocks include gap-up leaders OPENZ, NEXR and MFIC, and gap-down movers DVLT, SPRC and ARTV, with gap sizes and session moves.
Premarket movers ahead of the US open: BRAI, OPENZ, NEXR, XXII and AUROW among top gainers, while DVLT, SPRC, ARTV and ACTU lead declines.
aTyr’s common stock to begin trading on a post-split adjusted basis on October 29, 2026SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnolo
aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
Collaboration involves Company’s anti-NRP2 antibody ATYR2810 in preclinical studies of pediatric osteosarcoma.SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a cli
The collaboration will be led by Bang H. Hoang, M.D., Arnold and Madaleine Penner Professor and Co-Director of Orthopaedic Oncology in the Department of Orthopaedic Surgery at Montefiore Einstein. Dr. Hoang’s research
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -19.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ATYR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ATYR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, aTyr Pharma Inc. (ATYR) ranks #522 by composite RQD confidence (44/100, grade D) and #866 by equity capitalization ($13.5M). Within this direct 5-issuer industry benchmark cohort, ATYR leads on earnings valuation at N/A trailing P/E, while ATYR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PASG currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with ATYR at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ATYR
ACTIVE
aTyr Pharma Inc. | D | 44/100 | — | — | -35.0% | +4.56% | $13.5M | Benchmark Subject |
| BCDA BioCardia Inc. | D | 49/100 | — | — | -35.0% | -2.26% | $14.0M | /bcda-vs-atyr → |
| DYAI Dyadic International Inc. | E | 33/100 | — | 24.9% | -35.0% | -8.40% | $14.5M | /dyai-vs-atyr → |
| PASG Passage Bio Inc. | D | 51/100 | — | — | -35.0% | +5.71% | $11.3M | /pasg-vs-atyr → |
| PLUR Pluri Inc. | D- | 39/100 | — | 49.0% | -35.0% | -2.44% | $16.1M | /plur-vs-atyr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), aTyr Pharma Inc. (ATYR) reported GAAP revenue of $190.0K (-19.1% vs. FY2024 revenue of $235.0K , and -46.2% cumulative change since FY2023) , GAAP net income of -$74.1M, operating cash flow of -$62.0M, and free cash flow of -$62.1M (+10.3% YoY). On the balance sheet, ATYR closed FY2025 with $93.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $190.0K | -$74.1M | -$62.0M | -$62.1M | $93.0M | — |
| FY2024 (FY) | 2024-12-31 | $235.0K | -$64.0M | -$69.1M | -$69.2M | $96.8M | — |
| FY2023 (FY) | 2023-12-31 | $353.0K | -$50.4M | -$33.2M | -$33.2M | — | — |
As of 2026-11-01, aTyr Pharma Inc. (NASDAQ: ATYR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.37 (+4.56% 1D, market cap $13.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ATYR ranks #522 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ATYR carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCDA (BioCardia Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $14.0M) and DYAI (Dyadic International Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $14.5M). Among the 5-stock peer group, ATYR leads on earnings multiple (N/A) while ATYR leads on capital efficiency (-35.0% ROIC).
Per ATYR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001339970), aTyr Pharma Inc. generated $190.0K in revenue (-19.1% YoY), -$74.1M in net income, and -$62.1M in free cash flow against $93.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ATYR last traded at $5.37 (+4.56% on volume of 238,737 shares), positioning the stock +1120.45% above its 50-day simple moving average ($0.44) and +752.38% above its 200-day simple moving average ($0.63). Across its 52-week range of $4.08 to $44.40, ATYR sits at the 3.2% percentile with a 14-day RSI of 97.3 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($4.70 to $6.04).
Why ATYR Stock surged +4.56% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.